The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Supriya Lifescience Limited has reported standalone financial results for the period ended December 31, 2024.
Supriya Lifescience has posted net profit of Rs. 46.78 crores for the period ended December 31, 2024 as against net profit of Rs. 46.14 crores for the period ended September 30, 2024. The company posted net profit of Rs. 29.787 crores for the period ended December 31, 2023.
Supriya Lifescience has reported total income of Rs. 187.74 crores during the period ended December 31, 2024 as compared to Rs. 168.62 crores during the period ended September 30, 2024. The company reported total income of Rs. 143.139 crores during the period ended December 31, 2023.
For the 9 months period ended December 31, 2024, Supriya Lifescience has reported total income of Rs. 519.21 crores as compared to Rs. 420.63 crores during the 9 months period ended December 31, 2023.
The company has posted net profit of Rs. 137.57 crores for the 9 months period ended December 31, 2024 as against net profit of Rs. 82.18 crores for the 9 months period ended December 31, 2023.
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth."
Subscribe To Our Newsletter & Stay Updated